Eureka! Institutional Repository

DPP4 inhibitors inhibit the rapid in vivo inactivation of GPP-1 and GIP in inactive metabolites. In this way, the incretin effect of these hormones is achieved. The main representatives of this category are sitagliptin, vildagliptin, saxagliptin, linagliptin and atoliplin. Their advantage is that the risk for hypoglycemia is lower. Their disadvantage is that they have a high cost. Linagliptin has a half-life of 12 hours, is metabolised in the liver and excreted by 94% of the bile ducts and only 6% of the kidneys. This property gives linagliptin the privilege to be administered throughout the spectrum of chronic kidney disease (CKD) of diabetes even at an advanced dose-free stage with sufficient efficacy (a 0.6% reduction in HBN1 in severe CKD) and safety. Sodium glucose transporters (SGLT2 inhibitors) mediate proximal refractory renal tubules and contribute to glucose aspiration (as known daily 180 g of glucose, the coil is filtered and only 0.8 g is excreted from the urine 24 hours a day). SGLT2 inhibitors are membrane proteins that are involved not only in glucose transport but also in the transport of osmotically active substances and various ions through the intestinal epithelium and epithelium of the proximally infected renal tubule. The purpose of this diploma thesis is to investigate the effect of DPP4 inhibitors and SLGT2 inhibitors on blood pressure in patients with type 2 diabetes mellitus. To this end, 30 patients with type 2 diabetes mellitus were tested. The 15 patients were treated with DPP4 inhibitors and 15 patients with SLGT2 inhibitors. Blood pressure was measured by all 30 patients before starting their medication as well as after 2 months. The results of the survey were clear. In the group of patients treated with DPP4 inhibitors for 2 months, the reduction in both systolic (PFS) and diastolic (PAH) was not statistically significant. In contrast, patients who were treated with SLGT2 inhibitors experienced a tendency to reduce systolic pressure (PFS) and a statistically significant reduction in diastolic pressure (PAS). The resulting conclusions are that both DPP4 inhibitors and SLGT2 inhibitors could be used safely and without any risk in patients with type 2 diabetes mellitus.